Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi plans to change hospital drug-discount program, WSJ reports
12:32pm, Friday, 22'nd Nov 2024
French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income and uninsured patients, the Wall Street Journal reported on Friday.
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
04:01pm, Monday, 18'th Nov 2024
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase
10:49am, Monday, 18'th Nov 2024
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
European And US Vaccine Stocks Are Under Pressure - Here's WHy
11:21am, Friday, 15'th Nov 2024
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
01:00am, Friday, 15'th Nov 2024
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
11:42am, Thursday, 14'th Nov 2024
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with
Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform
07:00am, Wednesday, 13'th Nov 2024
CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indicatio
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
05:42am, Wednesday, 13'th Nov 2024
Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse drug portfolio and a robust pipeline of future drugs to market, this big phar
The Accumulus Platform Powers Sanofi's Submissions to Multiple Regulators Around the World
09:05am, Thursday, 07'th Nov 2024
BURLINGAME, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc. (“Accumulus”), is revolutionizing the scalability of reliance pathways, enabling a recent submission from Sanofi to mu
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
01:00am, Wednesday, 06'th Nov 2024
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on D
SandboxAQ CEO on the firm's partnership with Sanofi
03:27am, Tuesday, 05'th Nov 2024
Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical development.
Sanofi Cancels Consumer Healthcare Business Spin-Off
02:28pm, Wednesday, 30'th Oct 2024
Deal Overview
Resalis Therapeutics Gains Strategic Equity Investment from Sanofi
06:00am, Monday, 28'th Oct 2024
TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead invest
Why Sanofi Stock Flew Higher on Friday
05:23pm, Friday, 25'th Oct 2024
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
Sanofi (SNY) Q3 2024 Earnings Call Transcript
01:36pm, Friday, 25'th Oct 2024
Sanofi (NASDAQ:SNY ) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Thomas Kudsk - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger -
